Only recently, it has been shown, for example, that oral treatment of sphingomyelinase-deficient mice (model of the lysosomal storage disease Niemann–Pick type A/B) with FAAH inhibitors alleviated neuroinflammation, retarded neurodegeneration, improved behavioral alterations, and extended life span (32). Here, FAAH is linked to lysosomal storage disease.